Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical
company focused on developing and commercializing innovative
products for acute care settings, today reported financial results
for the three months ended March 31, 2021.
“The first quarter has been busy and fruitful at
Baudax. ANJESO sustained marked progress in the areas of new
account wins, increasing units sold, reorder rates, and deepening
usage across the hospital and ambulatory surgery center space.
Although we are seeing some relief from COVID in the marketplace,
it continues to impact elective surgical procedures and hospital
administration’s focus as well as access into accounts, which the
team will need to continue to monitor to maintain the growth of
ANJESO,” said Gerri Henwood, President and CEO of Baudax Bio. “We
continue to receive positive feedback from physicians using ANJESO
for the management of moderate to severe pain in the acute care
setting.”
First Quarter 2021 and Recent Business
Highlights
-
Continued Progress on U.S. Launch of ANJESO.
Baudax Bio built infrastructure, executed group purchasing
organization agreements with the top three medical distributors and
began developing awareness and knowledge of ANJESO in 2020. In the
first quarter of 2021 we have seen more meaningful progress in
deepening usage of ANJESO in early users as reflected in sales to
existing hospitals and ambulatory surgery centers, which doubled in
the first quarter of 2021 compared to the fourth quarter of 2020.
Total unit sales grew 40% in the first quarter of 2021 compared to
the fourth quarter of 2020 and the reorder rate was nearly 70% for
the same comparable period.During the first quarter, formulary wins
grew by 22 institutions, for a total of 90 institutions as of March
31, 2021, an increase of over 30% from the fourth quarter.
-
Publication of ANJESO Phase IIIb Data in Pain
Medicine. In April 2021, the company announced the online
publication of ANJESO Phase IIIb data in the peer-reviewed medical
journal Pain Medicine. The data highlights the safety and pain
management efficacy of preoperative ANJESO injection in total knee
arthroplasty (TKA). This study also reported that ANJESO decreased
the need for opioids following surgery. The findings published were
especially compelling because they suggest select measures of
health care resource utilization (HRU) were lower in the ANJESO
treated patients.
-
Announced Partial Adjournment of Annual Meeting of
Shareholders. In April 2021, Baudax Bio partially
adjourned its 2021 Annual Meeting of Shareholders solely with
respect to Proposal 3 set forth in its Definitive Proxy Statement
filed with the Securities and Exchange Commission on March 11,
2021. Proposal 3 is a proposal to amend the Company’s Amended and
Restated Articles of Incorporation to increase the number of
authorized, not issued, shares of common stock from 100 million
shares to 190 million shares. This adjournment provides its
shareholders additional time to vote on Proposal 3. The Annual
Meeting will resume with respect to Proposal 3 at 10:00 a.m.
Eastern time on May 6, 2021.
- Richard
S. Casten Strengthens Management Team in Chief Financial Officer
Role. In March 2021, Baudax Bio announced the appointment
of Richard S. Casten, CPA, MBA as Chief Financial Officer. In this
role, Mr. Casten will be responsible for leading and directing the
financial activities of the Company. Mr. Casten brings to Baudax
Bio 25 years of diversified financial experience across
pharmaceutical, Fortune 500 consumer products and public
accounting.
- In
February, Announced $17.6 Million Offering Priced At-the-Market
under Nasdaq Rules. Baudax Bio announced that it entered
into a definitive agreement with institutional and accredited
investors for the purchase and sale of an aggregate of 11,000,000
shares of common stock at a purchase price of $1.60 per share in a
registered direct offering, priced at-the-market under Nasdaq
rules. The gross proceeds from the offering were approximately
$17.6 million, prior to deducting fees and expenses.
- In
January, Announced Exercise of Warrants for Gross Proceeds of $13.4
Million. Baudax Bio announced the agreement by an
accredited healthcare-focused institutional investor to cash
exercise certain warrants to purchase up to an aggregate of
10,300,430 shares of common stock having an exercise price of $1.18
issued by the company in December 2020. In connection therewith,
Baudax Bio sold the exercising holder new warrants, which are cash
exercisable for an aggregate of 10,300,430 shares of common stock
at an exercise price of $1.60 per share, for an aggregate purchase
price $1,287,554, or $0.125 per warrant. The gross proceeds to
Baudax Bio from the exercise of the warrants and the sale of the
additional warrants was $13.4 million, prior to deducting fees and
expenses.
First Quarter 2021 Financial
Results
As of March 31, 2021, Baudax Bio had cash,
cash equivalents and short-term investments of
$38.2 million.
Net product revenue for the three months ended
March 31, 2021 was $0.2 million, related to sales of ANJESO in
the U.S. There was no product revenue recognized during the three
months ended March 31, 2020.
Cost of sales for the three months ended
March 31, 2021 was $0.8 million and consisted of product
costs, royalty expense and certain fixed costs associated with the
manufacturing of ANJESO including supply chain and quality costs.
Certain product costs of ANJESO units recognized as revenue during
the three months ended March 31, 2021 were incurred prior to
the FDA approval of ANJESO in February 2020, and therefore are not
included in cost of sales during the period. Baudax Bio expects
that over time, its cost of sales will increase as sales increase
and as inventory values change to include all direct and indirect
costs and expenses post FDA approval. No cost of sales was recorded
for the three months ended March 31, 2020.
Research and development expenses for the three
months ended March 31, 2021 were $1.1 million, compared
to $3.1 million for the three months ended March 31,
2020. The decrease of $2.0 million was primarily due to a
decrease of $1.7 million as a result of re-allocating costs related
to supply chain, regulatory, quality, and medical affairs
associated with support of the commercial launch of ANJESO from
research and development expense to cost of sales and selling,
general and administrative expense and a decrease in personnel
costs of $0.3 million.
Selling, general and administrative expenses for
the three months ended March 31, 2021 were $12.1 million,
compared to $8.0 million for the same prior year period. The
increase of $4.1 million was primarily due to the commercial
launch of ANJESO, specifically, an increase in personnel related
costs of $1.6 million, an increase of $1.3 million attributable to
medical affairs and regulatory support reallocated from research
and development expense post FDA approval, an increase of $0.3
million in public company costs and an increase of $0.3 million in
marketing costs. In addition, the first quarter of 2020 included
$0.5 million in reimbursed general and administrative expenses
related to the Transition Services Agreement with Recro Pharma,
which ended on December 31, 2020.
Baudax Bio reported a net loss, including
non-cash charges of $5.1 million, of $16.9 million, or $(0.27)
per share, for the three months ended March 31, 2021. The
non-cash charge of $5.1 million was associated with
stock-based compensation, non-cash interest expense, depreciation,
amortization, changes in warrant valuations, and changes in fair
value of contingent consideration. This compares to a net loss,
including non-cash charges of $32.0 million, of $40.3 million,
or $(4.03) per share, for the comparable period in 2020. The
non-cash charge of $32.0 million in 2020 was associated with
changes in fair value of contingent consideration, stock-based
compensation, change in warrant valuation, depreciation and
amortization.
About Baudax Bio
Baudax Bio is a pharmaceutical company focused
on developing and commercializing innovative products for acute
care settings. The launch of Baudax Bio’s first commercial product
ANJESO® began in mid-2020. ANJESO is the first and only 24-hour,
intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory
(NSAID) for the management of moderate to severe pain, which can be
administered alone or in combination with other non-NSAID
analgesics. It has successfully completed three Phase III clinical
trials, including two pivotal efficacy trials, a large double-blind
Phase III safety trial and a Phase IIIb program evaluating ANJESO
and its health economic impact in specific surgical settings. In
addition to ANJESO, Baudax Bio has a pipeline of other innovative
pharmaceutical assets including two novel neuromuscular blocking
agents (NMBAs) and a proprietary chemical reversal agent specific
to these NMBAs which is currently in preclinical studies. For more
information, please visit www.baudaxbio.com.
Cautionary Statement Regarding Forward
Looking Statements
This press release contains forward-looking
statements that involve risks and uncertainties. Such
forward-looking statements reflect Baudax Bio’s expectations about
its future performance and opportunities that involve substantial
risks and uncertainties. When used herein, the words “anticipate,”
“believe,” “estimate,” “may,” “upcoming,” “plan,” “target,” “goal,”
“intend,” and “expect,” and similar expressions, as they relate to
Baudax Bio or its management, are intended to identify such
forward-looking statements. These forward-looking statements are
based on information available to Baudax Bio as of the date of
publication on this internet site and are subject to a number of
risks, uncertainties, and other factors that could cause Baudax
Bio’s performance to differ materially from those expressed in, or
implied by, these forward-looking statements. These forward-looking
statements are subject to risks and uncertainties including, among
other things, the ongoing economic and social consequences of the
COVID-19 pandemic, including any adverse impact on the commercial
launch of ANJESO® or disruption in supply chain, Baudax Bio’s
ability to maintain regulatory approval for ANJESO, Baudax Bio’s
ability to successfully commercialize ANJESO; the acceptance of
ANJESO by the medical community, including physicians, patients,
health care providers and hospital formularies; Baudax Bio’s
ability and that of Baudax Bio’s third party manufacturers to
successfully scale-up our commercial manufacturing process for
ANJESO, Baudax Bio’s ability to produce commercial supply in
quantities and quality sufficient to satisfy market demand for
ANJESO, Baudax Bio’s ability to raise future financing for
continued product development, payment of milestones and ANJESO
commercialization, Baudax Bio’s ability to pay its debt and satisfy
conditions necessary to access future tranches of debt, Baudax
Bio’s ability to comply with the financial and other covenants
under its credit facility, Baudax Bio’s ability to manage costs and
execute on our operational and budget plans, the accuracy of Baudax
Bio’s estimates of the potential market for ANJESO, Baudax Bio’s
ability to achieve its financial goals; and Baudax Bio’s ability to
obtain, maintain and successfully enforce adequate patent and other
intellectual property protection. These forward-looking statements
should be considered together with the risks and uncertainties that
may affect Baudax Bio’s business and future results included in
Baudax Bio’s filings with the Securities and Exchange Commission at
www.sec.gov. These forward-looking statements are based on
information currently available to Baudax Bio, and Baudax Bio
assumes no obligation to update any forward-looking statements
except as required by applicable law.
CONTACTS:Investor
Relations Contact:Argot PartnersSam Martin / Claudia
Styslinger(212)
600-1902sam@argotpartners.comclaudia@argotpartners.com
Media Contact:Argot
PartnersDavid Rosen(212) 600-1902david.rosen@argotpartners.com
BAUDAX BIO, INC.Consolidated
Balance Sheets(Unaudited)
(amounts in thousands,
except share and per share data) |
|
March 31, 2021 |
|
|
December 31, 2020 |
|
Assets |
|
|
|
|
|
|
|
|
Current
assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
30,690 |
|
|
$ |
30,342 |
|
Short-term investments |
|
|
7,495 |
|
|
|
— |
|
Accounts receivable, net |
|
|
163 |
|
|
|
51 |
|
Inventory, net |
|
|
2,773 |
|
|
|
2,978 |
|
Prepaid expenses and other current assets |
|
|
2,569 |
|
|
|
3,346 |
|
Total current assets |
|
|
43,690 |
|
|
|
36,717 |
|
Property, plant and equipment, net |
|
|
5,039 |
|
|
|
5,052 |
|
Intangible assets, net |
|
|
23,610 |
|
|
|
24,254 |
|
Goodwill |
|
|
2,127 |
|
|
|
2,127 |
|
Other
long-term assets |
|
|
520 |
|
|
|
583 |
|
Total assets |
|
$ |
74,986 |
|
|
$ |
68,733 |
|
Liabilities and Shareholders' Equity |
|
|
|
|
|
|
|
|
Current
liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
1,140 |
|
|
$ |
3,653 |
|
Accrued expenses and other current liabilities |
|
|
4,680 |
|
|
|
5,326 |
|
Current portion of long-term debt, net |
|
|
1,196 |
|
|
|
683 |
|
Current portion of contingent consideration |
|
|
7,107 |
|
|
|
8,467 |
|
Total current liabilities |
|
|
14,123 |
|
|
|
18,129 |
|
Long-term debt, net |
|
|
8,185 |
|
|
|
8,469 |
|
Warrant
liability |
|
|
83 |
|
|
|
65 |
|
Long-term portion of contingent consideration |
|
|
53,348 |
|
|
|
56,576 |
|
Other
long-term liabilities |
|
|
241 |
|
|
|
293 |
|
Total liabilities |
|
|
75,980 |
|
|
|
83,532 |
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
Shareholders’ equity: |
|
|
|
|
|
|
|
|
Preferred stock, $0.01 par value. Authorized, 10,000,000 shares;
none issued and outstanding |
|
|
— |
|
|
|
— |
|
Common stock, $0.01 par value. Authorized, 100,000,000 shares;
issued and outstanding, 70,142,608 shares at March 31, 2021
and 48,688,480 shares at December 31, 2020 |
|
|
701 |
|
|
|
487 |
|
Additional paid-in capital |
|
|
127,537 |
|
|
|
97,034 |
|
Accumulated deficit |
|
|
(129,232 |
) |
|
|
(112,320 |
) |
Total shareholders’ equity (deficit) |
|
|
(994 |
) |
|
|
(14,799 |
) |
Total liabilities and shareholders’ equity |
|
$ |
74,986 |
|
|
$ |
68,733 |
|
BAUDAX BIO, INC.Consolidated and
Combined Statements of Operations(Unaudited)
|
|
For the Three Months Ended March 31, |
|
(amounts in thousands,
except share and per share data) |
|
2021 |
|
|
2020 |
|
Revenue, net |
|
$ |
198 |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
Cost of sales |
|
|
821 |
|
|
|
— |
|
Research and development |
|
|
1,108 |
|
|
|
3,070 |
|
Selling, general and administrative |
|
|
12,088 |
|
|
|
8,046 |
|
Amortization of intangible assets |
|
|
644 |
|
|
|
215 |
|
Change in warrant valuation |
|
|
18 |
|
|
|
1,378 |
|
Change in contingent consideration valuation |
|
|
1,841 |
|
|
|
27,626 |
|
Total operating expenses |
|
|
16,520 |
|
|
|
40,335 |
|
Operating loss |
|
|
(16,322 |
) |
|
|
(40,335 |
) |
Other
expense: |
|
|
|
|
|
|
|
|
Interest and other expense |
|
|
(590 |
) |
|
|
37 |
|
Net loss |
|
$ |
(16,912 |
) |
|
$ |
(40,298 |
) |
|
|
|
|
|
|
|
|
|
Per
share information: |
|
|
|
|
|
|
|
|
Net loss
per share of common stock, basic and diluted |
|
$ |
(0.27 |
) |
|
$ |
(4.03 |
) |
Weighted
average common shares outstanding, basic and diluted |
|
|
62,584,129 |
|
|
|
10,001,228 |
|
|
|
|
|
|
|
|
|
|
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Apr 2023 to Apr 2024